Get the Stockscreener App
86.97
0.49%
0.42
After Hours:
86.92
-0.05
-0.06%
Arrowhead Pharmaceuticals Inc stock is traded at $86.97, with a volume of 1.91M.
It is up +0.49% in the last 24 hours and up +18.99% over the past month.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
See More
Previous Close:
$86.55
Open:
$87.275
24h Volume:
1.91M
Relative Volume:
0.95
Market Cap:
$12.25B
Revenue:
$622.01M
Net Income/Loss:
$-271.86M
P/E Ratio:
-40.48
EPS:
-2.1484
Net Cash Flow:
$-45.87M
1W Performance:
+6.70%
1M Performance:
+18.99%
6M Performance:
+32.39%
1Y Performance:
+416.45%
1-Day Range:
$83.79
$87.57
1-Week Range:
$78.81
$87.83
52-Week Range:
$14.30
$87.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
86.97 | 12.19B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals stock hits 52-week high at 84.65 USD - Investing.com
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR - TradingView
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy - Investing.com
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
ARWR Maintained by Chardan Capital -- Price Target Steady at $90 - GuruFocus
Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital - Moomoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development ProgramsSlideshow (NASDAQ:ARWR) 2026-06-30 - Seeking Alpha
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from Russell 2000 Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals Inc R&D Webinar (Virtual) Transcript - GuruFocus
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Dynamic Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 3000E Value Benchmark - marketscreener.com
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR) - TradingView
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (SWB:HDP1) - TradingView
HDP1 Forecast — Price Target — Prediction for 2027 - TradingView
A2AGYB Forecast — Price Target — Prediction for 2027 - TradingView
ARWR Forecast — Price Target — Prediction for 2027 - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Liquidity Mapping Around (ARWR) Price Events - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Leads Healthcare Stocks with St - GuruFocus
Arrowhead Pharmaceuticals gets EC approval for REDEMPLO in FCS - grafa.com
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP - GuruFocus
EU approves Arrowhead's REDEMPLO for rare fat disorder FCS - Stock Titan
The Insider Report: Stocks Celebrate Peace and a New Fed Chapter - Benzinga
Are Arrowhead Pharmaceuticals’ (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative? - Sahm
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update - Sahm
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Business Wire
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrowhead Pharmaceuticals Inc - TradingKey
Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran - Quiver Quantitative
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 - Investing.com
ARWR Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership - Stock Titan
Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant - Stock Titan
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):